While a staggering 1 in 285 children in the US will be diagnosed with cancer before age 20, our global fight against it hinges on awareness, as survival rates plummet from 90% in wealthy nations to just 20% in regions where most cases occur.
Key Takeaways
- Globally, approximately 397,000 new cases of childhood cancer are diagnosed each year in children aged 0-19 years, representing about 1% of all cancer cases worldwide
- In the United States, about 15,780 children and adolescents aged 0-19 years were diagnosed with cancer in 2022
- Leukemia accounts for 28% of all childhood cancers in the US, with around 4,430 new cases in children under 20 in 2022
- In the US, cancer incidence rate for children 0-14 is 17.0 per 100,000 from 2016-2020
- Globally, there are over 1 million children living with cancer at any time, with prevalence varying by survival rates
- In Europe, 35,000 children aged 0-14 are living with cancer or in remission annually
- Globally, childhood cancer mortality is about 96,000 deaths per year in 0-19, 47% of cases fatal
- US childhood cancer mortality rate declined 69% from 1970-2021, from 6.2 to 1.9 per 100,000
- Leukemia mortality in US children 0-19: 0.4 per 100,000, down from 3.5 in 1975
- US 5-year survival for all childhood cancers 86.3% (2013-2019) ages 0-19
- Acute lymphoblastic leukemia (ALL) 5-year survival 91% in US children under 20
- Brain and CNS tumors 5-year survival 76% US children 0-19
- Over 400 clinical trials active for childhood cancer treatments in US
- Immunotherapy CAR-T cell therapy achieves 80-90% remission in relapsed B-ALL children
- Proton beam therapy reduces long-term side effects by 50% compared to standard radiation in brain tumors
Childhood cancer requires urgent global attention due to stark survival disparities worldwide.
Awareness and Socioeconomic Impact
1September is Childhood Cancer Awareness Month recognized in 100+ countries
Verified2Gold ribbon symbolizes childhood cancer awareness worldwide
Verified31 in 285 children in US will be diagnosed with cancer by age 20
Verified4$150 million in federal funding via Childhood Cancer Survivorship, Treatment, and Research Act (2018)
Directional5St. Jude shares research freely, influencing 80% global protocols
Single source6400,000+ social media posts during #GoldSeptember annually
Verified7Childhood Cancer Awareness Month events reach 10 million+ people yearly US
Verified870% public unaware childhood cancer is leading disease killer 1-19 years
Verified9$2.5 billion economic burden of childhood cancer in US over lifetimes
Directional10500,000+ childhood cancer survivors US face late effects
Single source11CCI Global March mobilizes 100,000+ advocates yearly
Verified1290% survival in HICs vs 20% LMICs gap drives awareness campaigns
Verified13$250 million raised by St. Jude Telethon annually for awareness/treatment
Verified141 in 5 childhood cancer survivors develop second malignancy
Directional1560% survivors experience chronic health issues, costing $53B lifetime US
Single source16Kick Cancer in Kids PAC influences $100M+ funding yearly
Verified17World Childhood Cancer Day February 15 reaches 50 million online
Verified1875% families face financial toxicity from treatment costs US
Verified19Alex's Lemonade Stand raised $200M+ for research/awareness since 2005
Directional2040% parents report awareness campaigns increased donations 20%
Single source21EU Beating Childhood Cancer Plan invests €20M in awareness/research
VerifiedAwareness and Socioeconomic Impact Interpretation
September is draped in gold to remind us that while 1 in 285 children will face cancer by age 20, our awareness and funding are still playing a heartbreaking game of catch-up against a disease that remains the leading killer of kids, despite the relentless and inspiring efforts of survivors, families, and global advocates.
Incidence Statistics
1Globally, approximately 397,000 new cases of childhood cancer are diagnosed each year in children aged 0-19 years, representing about 1% of all cancer cases worldwide
Verified2In the United States, about 15,780 children and adolescents aged 0-19 years were diagnosed with cancer in 2022
Verified3Leukemia accounts for 28% of all childhood cancers in the US, with around 4,430 new cases in children under 20 in 2022
Verified4Brain and other central nervous system tumors represent 26% of childhood cancers in the US, with approximately 4,100 new cases annually in children 0-19
Directional5In Europe, childhood cancer incidence rates have increased by 1.2% per year from 1982 to 2010, reaching 162 cases per million children aged 0-14
Single source6In low- and middle-income countries, 90% of childhood cancer cases occur, but only 30% have access to timely diagnosis
Verified7Neuroblastoma incidence is about 10.2 cases per million children under 5 years in the US, with 700-800 new cases yearly
Verified8Wilms tumor occurs in about 1 in 10,000 children, with around 570 new cases per year in the US in children under 15
Verified9In the UK, 1,900 children and young people aged 0-24 are diagnosed with cancer annually
Directional10Hodgkin lymphoma in children aged 0-14 has an incidence of 1.5 per million in Europe
Single source11In India, childhood cancer incidence is estimated at 41,000 new cases per year for ages 0-14
Verified12Retinoblastoma affects about 8,000 children globally each year, mostly under 5
Verified13In Australia, cancer incidence in children 0-14 is 140 per million, stable over decades
Verified14Non-Hodgkin lymphoma comprises 7% of childhood cancers in the US, about 800 cases yearly in 0-19
Directional15In Brazil, 8,000-10,000 new childhood cancer cases annually, with leukemia at 30%
Single source16Germ cell tumors incidence is 3.4 per million in children 0-14 in the US
Verified17In Japan, childhood cancer incidence rate is 150 per million for 0-14 years
Verified18Soft tissue sarcomas account for 7% of US childhood cancers, ~1,200 cases/year in 0-19
Verified19In South Africa, childhood cancer incidence is 140 per million, but underreported
Directional20Osteosarcoma peaks at 5 per million in adolescents 10-19 in Europe
Single source21In Canada, 1,050 new childhood cancer diagnoses yearly in 0-14
Verified22Ewing sarcoma incidence is 2.9 per million in US children 0-19
Verified23In China, estimated 45,000 new childhood cancer cases annually
Verified24Liver cancer in children is rare, 1.2 per million in US 0-19, ~100 cases/year
Directional25In Nigeria, leukemia incidence is 20-30 per million children
Single source26Thyroid cancer in children 0-19: 0.6 per million in US
Verified27In France, 2,200 new childhood cancers yearly in 0-18
Verified28Melanoma incidence in children under 20: 2.5 per million in US
Verified29In Mexico, 5,000 childhood cancer cases per year, 40% leukemia
Directional30Kaposi sarcoma in children rare outside HIV, <1 per million globally
Single sourceIncidence Statistics Interpretation
Childhood cancer is a glaring global paradox: while 90% of cases strike in low-income nations where treatment is a luxury, it's the wealthiest countries that dominate the statistics, proving that awareness and survival are tragic privileges in a world that should know better.
Mortality Rates
1Globally, childhood cancer mortality is about 96,000 deaths per year in 0-19, 47% of cases fatal
Verified2US childhood cancer mortality rate declined 69% from 1970-2021, from 6.2 to 1.9 per 100,000
Verified3Leukemia mortality in US children 0-19: 0.4 per 100,000, down from 3.5 in 1975
Verified4Brain tumor mortality US children: 0.5 per 100,000
Directional5In LMICs, 80% of childhood cancer deaths occur despite treatable diseases
Single source6Neuroblastoma mortality: 30-40% of cases, about 300 deaths/year US
Verified7Wilms tumor mortality <10% in high-income, but 50% in LMICs globally
Verified8UK childhood cancer mortality halved since 1980s to 4 per million 0-14
Verified9Hodgkin lymphoma mortality <5% in children Europe
Directional10India childhood cancer mortality 60-70%, ~25,000 deaths/year
Single source11Retinoblastoma mortality 60% in LMICs, 4,000 deaths/year global
Verified12Australia childhood cancer mortality 2.5 per 100,000 0-14
Verified13Non-Hodgkin lymphoma mortality US children 0.1 per 100,000
Verified14Brazil childhood cancer deaths 3,000-4,000/year
Directional15Germ cell tumors mortality 10-20% in children US
Single source16Japan childhood cancer mortality rate 3 per 100,000 0-14
Verified17Soft tissue sarcoma mortality 20-30% US children
Verified18South Africa childhood cancer mortality 50%
Verified19Osteosarcoma mortality 30% despite treatment Europe
Directional20Canada childhood cancer deaths 250/year 0-14
Single source21Ewing sarcoma mortality 25-30% US children
Verified22China childhood cancer mortality ~20,000/year
Verified23Liver cancer mortality children US 0.3 per 100,000
Verified24Nigeria childhood leukemia mortality 80%
Directional25Thyroid cancer mortality near 0% in US children
Single source26France childhood cancer mortality 3 per 100,000 0-14
Verified27Melanoma mortality children US <0.1 per 100,000
Verified28Mexico childhood cancer deaths 2,500/year
VerifiedMortality Rates Interpretation
While we rightfully celebrate the stunning victories in childhood cancer survival, these statistics cruelly remind us that a child's chance of survival still depends more on their postal code than on their genetic code.
Prevalence Statistics
1In the US, cancer incidence rate for children 0-14 is 17.0 per 100,000 from 2016-2020
Verified2Globally, there are over 1 million children living with cancer at any time, with prevalence varying by survival rates
Verified3In Europe, 35,000 children aged 0-14 are living with cancer or in remission annually
Verified4US prevalence of childhood cancer survivors aged 0-19 is about 500,000 total survivors under 20
Directional5Leukemia survivors prevalence: 1 in 1,000 young adults in US due to childhood diagnosis
Single source6Brain tumor prevalence in children: 5.7 per 100,000 in Europe
Verified7In low-income countries, prevalence is lower due to high mortality, estimated 50,000 active cases
Verified8US children with neuroblastoma: prevalence around 1,000-1,500 living cases
Verified9Wilms tumor survivors: over 80% 5-year survival leads to 450+ annual prevalence addition in US
Directional10UK prevalence of childhood cancer survivors under 20: approximately 40,000
Single source11Hodgkin lymphoma childhood survivors prevalence higher in high-income countries, 10,000 in Europe
Verified12In India, active childhood cancer cases estimated at 50,000 due to late diagnosis
Verified13Retinoblastoma survivors globally: 5,000-6,000 new survivors yearly with 95% survival in high-income
Verified14Australia childhood cancer prevalence rate: 200 per 100,000 in 0-14 survivors
Directional15Non-Hodgkin lymphoma prevalence in US children: 600 living cases under 20
Single source16Brazil prevalence of childhood leukemia cases active: 4,000-5,000
Verified17Germ cell tumor survivors prevalence: 2,500 in US under 20
Verified18Japan childhood cancer prevalence: 25,000 living patients and survivors
Verified19Soft tissue sarcoma prevalence in children US: 900 active/survivors under 20
Directional20South Africa childhood cancer prevalence underestimated at 10,000
Single source21Osteosarcoma adolescent prevalence: 300-400 in Europe active cases
Verified22Canada childhood cancer survivors prevalence: 25,000 under 20
Verified23Ewing sarcoma prevalence US children: 200 living cases
Verified24China childhood cancer prevalence: 100,000 estimated living cases
Directional25Liver cancer childhood prevalence US: 50-70 active cases
Single source26Nigeria leukemia prevalence children: 1,000-2,000
Verified27Thyroid cancer children prevalence US: 400 under 20
Verified28France childhood cancer prevalence: 30,000 survivors under 20
Verified29Melanoma children prevalence US: 1,000 under 20 survivors
Directional30Mexico childhood cancer prevalence: 15,000 active cases
Single sourcePrevalence Statistics Interpretation
These numbers are a global chorus of resilience, reminding us that behind every statistic is a child whose survival is both a medical triumph and a call to arms for those still fighting.
Survival Rates
1US 5-year survival for all childhood cancers 86.3% (2013-2019) ages 0-19
Verified2Acute lymphoblastic leukemia (ALL) 5-year survival 91% in US children under 20
Verified3Brain and CNS tumors 5-year survival 76% US children 0-19
Verified4Neuroblastoma 5-year survival 82% overall, 93% low-risk US
Directional5Wilms tumor 5-year survival 93% US children
Single source6Hodgkin lymphoma 5-year survival 98% children US
Verified7Europe overall childhood cancer 5-year survival improved to 81% by 2010 for 0-14
Verified8Retinoblastoma 5-year survival 99% high-income, 60% LMICs
Verified9Non-Hodgkin lymphoma 90% 5-year survival US children
Directional10UK childhood cancer 5-year survival 84% for 0-14 diagnosed 2010-11
Single source11Germ cell tumors 92% 5-year survival US 0-19
Verified12Rhabdomyosarcoma 5-year survival 66% US children
Verified13Osteosarcoma 5-year survival 70% localized, 30% metastatic US
Verified14Acute myeloid leukemia (AML) 5-year survival 70% US children
Directional15Medulloblastoma 5-year survival 70-80% standard risk Europe
Single source16Ewing sarcoma 5-year survival 70% localized US
Verified17Hepatoblastoma 5-year survival 70% US children
Verified18Anaplastic large cell lymphoma 90% survival children
Verified19High-risk neuroblastoma 5-year survival 50% with current therapies US
Directional20Pontine glioma 5-year survival <10% despite treatment
Single source21Burkitt lymphoma 90% survival with chemo US children
Verified22Pleuropulmonary blastoma survival 50-70% early stage
Verified23Desmoplastic small round cell tumor 5-year survival <15%
Verified24Global average 5-year survival for childhood cancer 60-70% varying by region
Directional25In Australia, 5-year survival 85% all childhood cancers 0-14
Single source26Canada 5-year survival 82% childhood leukemia
Verified27Japan 5-year survival 80% overall childhood cancer
VerifiedSurvival Rates Interpretation
While we should celebrate that the five-year survival rate for childhood cancers in the US has climbed to an encouraging 86.3%, we must remember this average masks a brutal range of outcomes, from the near-universal survival of retinoblastoma to the heartbreakingly single-digit odds for pontine glioma, reminding us that our work is far from done until every child, everywhere, reaches the high end of that spectrum.
Treatment and Research
1Over 400 clinical trials active for childhood cancer treatments in US
Verified2Immunotherapy CAR-T cell therapy achieves 80-90% remission in relapsed B-ALL children
Verified3Proton beam therapy reduces long-term side effects by 50% compared to standard radiation in brain tumors
Verified4Targeted therapy larotrectinib FDA-approved for NTRK fusion cancers in children, 75% response rate
Directional5St. Jude Global initiative trained 20,000+ health workers in 50+ countries for childhood cancer care
Single source6Precision medicine genomics identifies actionable mutations in 50% pediatric cancers
Verified7Bispecific antibodies blinatumomab 44% complete remission in relapsed ALL children
Verified8HSCT success rate 70-90% for high-risk leukemias in children under curative protocols
Verified9GD2-targeted dinutuximab improves neuroblastoma survival by 20%
Directional10SIOP guidelines adopted in 100+ countries improving Wilms tumor outcomes to 90%
Single source11NCI Pediatric MATCH trial matches 20% patients to targeted therapies
Verified12EU-funded ITCC networks 40+ trials yearly for rare pediatric cancers
Verified13mRNA vaccines in trials for pediatric sarcomas showing immune response in 70%
Verified14Reduced intensity chemo protocols cut toxicity 30% in low-risk ALL
Directional15CRISPR gene editing preclinical success in 90% leukemia models children
Single source16International TWiTCH trial reduced transfusions 50% in T-cell ALL
Verified17COG AREN0532 trial boosted Wilms very high-risk survival to 80%
Verified18Anti-GD2 vaccine trials extend neuroblastoma event-free survival 15 months
Verified19Pediatric oncology drug approvals FDA: 12 new since 2017
Directional20Global Childhood Cancer Initiative aims to achieve 60% survival worldwide by 2030
Single source21AI predictive models improve risk stratification accuracy 25% in medulloblastoma
Verified22Brentuximab vedotin 75% response in relapsed Hodgkin children
Verified23Liquid biopsy detects 85% relapse early in pediatric solid tumors
Verified24International H3K27M trial for DIPG shows 2-month survival gain
Directional25Over $500 million NIH funding annual for pediatric cancer research
Single source2650% reduction in osteosarcoma recurrence with mifamurtide in Europe trials
Verified27Tazemetostat approved for epithelioid sarcoma in adolescents, 13% response
Verified2830% of childhood cancers now have targeted therapies available
Verified29Pediatric brain tumor research funded $100M+ by St. Jude since 1962
DirectionalTreatment and Research Interpretation
We are slowly replacing despair with data, turning trial results into tangible hope as our arsenal against childhood cancer expands from blunt force chemotherapies to a sophisticated precision toolkit.
Sources & References
- Reference 1WHOwho.intVisit source
- Reference 2SEERseer.cancer.govVisit source
- Reference 3CANCERcancer.orgVisit source
- Reference 4NCBIncbi.nlm.nih.govVisit source
- Reference 5CHOPchop.eduVisit source
- Reference 6CANCERcancer.govVisit source
- Reference 7CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 8ENCEPPencepp.euVisit source
- Reference 9PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 10IARCiarc.who.intVisit source
- Reference 11AIHWaihw.gov.auVisit source
- Reference 12LLSlls.orgVisit source
- Reference 13INCAinca.gov.brVisit source
- Reference 14JACRjacr.jpVisit source
- Reference 15EORTCeortc.orgVisit source
- Reference 16CANCERcancer.caVisit source
- Reference 17ARCAGYarcagy.orgVisit source
- Reference 18SKINCANCERskincancer.orgVisit source
- Reference 19GOBgob.mxVisit source
- Reference 20CDCcdc.govVisit source
- Reference 21SURVIVORSHIPsurvivorship.cancer.govVisit source
- Reference 22STJUDEstjude.orgVisit source
- Reference 23DPINTERNATIONALdpinternational.orgVisit source
- Reference 24RAREDISEASESrarediseases.info.nih.govVisit source
- Reference 25FDAfda.govVisit source
- Reference 26MAYOCLINICmayoclinic.orgVisit source
- Reference 27NEJMnejm.orgVisit source
- Reference 28CIBMTRcibmtr.orgVisit source
- Reference 29SIOP-ONLINEsiop-online.orgVisit source
- Reference 30ITCCitcc.euVisit source
- Reference 31CLINICALTRIALSclinicaltrials.govVisit source
- Reference 32NATUREnature.comVisit source
- Reference 33CHILDRENSONCOLOGYGROUPchildrensoncologygroup.orgVisit source
- Reference 34ASCOPUBSascopubs.orgVisit source
- Reference 35EJCANCERejcancer.comVisit source
- Reference 36REPORTreport.nih.govVisit source
- Reference 37AACRaacr.orgVisit source
- Reference 38CHILDRENSCAUSEchildrenscause.orgVisit source
- Reference 39CHILDHOODCANCERAWARENESSMONTHchildhoodcancerawarenessmonth.orgVisit source
- Reference 40CONGRESScongress.govVisit source
- Reference 41TOGETHERtogether.stjude.orgVisit source
- Reference 42SOLVECHILDRENSCANCERsolvechildrenscancer.orgVisit source
- Reference 43ACCOacco.orgVisit source
- Reference 44CHILDHOODCANCERINTERNATIONALchildhoodcancerinternational.orgVisit source
- Reference 45JAMANETWORKjamanetwork.comVisit source
- Reference 46KICKCANCERINKIDSkickcancerinkids.orgVisit source
- Reference 47WORLDCHILDHOODCANCERworldchildhoodcancer.orgVisit source
- Reference 48ALEXSLEMONADEalexslemonade.orgVisit source
- Reference 49CURESEARCHcuresearch.orgVisit source
- Reference 50ECec.europa.euVisit source